| Abstrakt: |
Background: Diabetes is one of the most common diseases compared to others. There are many drugs available in the market to treat diabetes. Still, most of them have adverse drug reactions like hypoglycemia, weight gain, and subtherapeutic drug concentrations. SGLT-2 inhibitors are a new class of drugs used as add-on therapy to treat type-2 Diabetes Mellitus. They act by inhibiting glucose reabsorption and increasing glucose excretion via the kidneys. In an average adult, two kidneys filter about 180g of glucose per day. About 98% of the glucose filtered in the kidneys get reabsorbed in the proximal convoluted tubule back into the bloodstream, which can be inhibited by SGLT-2 inhibitors. Method: A systematic review and meta-analysis were performed on randomized clinical trial data, extracted from PubMed, Cochrane and Embase. All data, including baseline and shift of baseline, standard deviation, and number of participants, were recorded for HbA1c, Fasting blood glucose (FBG), Bodyweight and SBP/DBP. Results: Twelve randomized clinical trials, including 8000 participants, were compared and divided into three groups of drugs: SAXA+DAPA+MET, SAXA+MET and DAPA+MET. The comparison is done for HbA1c (WMD:-6.78; 95% CI:-8.28; P <0.00001) (WMD:-4.88; 95% CI:-6.93; P <0.00001), FBG (SMD: - 6.50; 95% CI: -8.55, -4.45; P <0.00001) (SMD: -7.75; 95% CI: -8.84, -6.66; P<0.00005,), body weight (SMD: 0.30; 95% CI: 0.27, 0.33; P =1.00) (SMD: -1.00; 95% CI: -1.90, -0.10; P<0.00001). Conclusion: Dapagliflozin, when given in combination, shows a major improvement in HbA1c and FBG levels and does not affect body weight. It was shown to be more effective when given in triple combination therapy. [ABSTRACT FROM AUTHOR] |
